FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3211117524> ?p ?o ?g. }

• W3211117524 endingPage "S58" @default.
• W3211117524 startingPage "S57" @default.
• W3211117524 abstract "Introduction: Immune checkpoint inhibitors (ICI) have revolutionized management of advanced malignancies, but predispose to toxicities such as immune-mediated diarrhea and colitis (IMDC). Systematic management strategy including early evaluation, diagnosis, treatment and close follow up of IMDC ensures high efficacy of clinical remission and reduces the delay and interruption of cancer treatment. We evaluate the quality outcomes of cancer patients in regards to IMDC and cancer after implementation of an institutional practice change following a standardized algorithm by a dedicated toxicity GI service among inpatients in a tertiary cancer hospital. Methods: This is a retrospective quality improvement study comparing outcomes of inpatients admitted with IMDC among years 2017 and 2019. IMDC practice algorithm was implemented in 10/2017. Results: Our sample includes 59 and 67 patients admitted for IMDC in 2017 and 2019 respectively. Genitourinary cancer is the most frequent cancer type (36%) followed by melanoma (23%). Baseline IMDC characteristics are shown in Table-1. We found no significant differences in duration, number of ICI treatments or time from ICI exposure to IMDC as well as clinical severity of IMDC in both groups. Patients admitted in 2019 had significantly higher rates of GI consultation (82% vs 53%, p< 0.001), endoscopic evaluation (70% vs 49%, P=0.01) and acceptance of GI medical management recommendations (55% vs 34%, P=0.015). Same group of patients more frequently received SIT as opposed to 2017 during their index hospital admission (41% vs 21%, P=0.039) which notably translated into significantly lower days to clinical remission (4 vs 10, P=0.046), hospital re-admissions (25% vs 51%, P=0.002) and recurrence of IMDC (24% vs 49%, P=0.002). Patients in 2019 had higher portion of close post discharge GI follow up compared to 2017 (50% vs 32%, P=0.038), and the dedicated IMDC GI specialist follow up contributed to better overall survival (P=0.003, Figure-1). Conclusion: Early evaluation, aggressive treatment and close post hospital follow up by a dedicated toxicity GI service is associated with earlier clinical remission, lower re-admissions, lower recurrence and better overall survival among inpateints with IMDC through a systematic management algorithm. We speculate the substantial improvement in quality of care and outcome of these complex cancer patients with the early involvement of an expert service specialized in this field.Figure 1:: GI follow up vs not Hazard ratio: 0.473 (0.285 - 0.783) P = 0.003Table 1:: IMDC related characteristics in patients treated for colitis in 2017 and 2019 (N=126). ICI: immune checkpoint inhibitor, IMDC: immune mediated diarrhea and colitis; IQR: interquartile range; IV: intravenous" @default.
• W3211117524 created "2021-11-08" @default.
• W3211117524 creator A5022891322 @default.
• W3211117524 creator A5036551662 @default.
• W3211117524 creator A5042917768 @default.
• W3211117524 creator A5050183505 @default.
• W3211117524 creator A5072363263 @default.
• W3211117524 creator A5073007668 @default.
• W3211117524 date "2021-10-01" @default.
• W3211117524 modified "2023-09-27" @default.
• W3211117524 title "S132 Focused Expertise of IOTox GI Service Can Improve Quality of Clinical Care and Outcome of Immune Mediated Diarrhea/Colitis Among Inpatients: A Retrospective Review and Quality Improvement Project" @default.
• W3211117524 doi "https://doi.org/10.14309/01.ajg.0000773000.80092.4c" @default.
• W3211117524 hasPublicationYear "2021" @default.
• W3211117524 type Work @default.
• W3211117524 sameAs 3211117524 @default.
• W3211117524 citedByCount "0" @default.
• W3211117524 crossrefType "journal-article" @default.
• W3211117524 hasAuthorship W3211117524A5022891322 @default.
• W3211117524 hasAuthorship W3211117524A5036551662 @default.
• W3211117524 hasAuthorship W3211117524A5042917768 @default.
• W3211117524 hasAuthorship W3211117524A5050183505 @default.
• W3211117524 hasAuthorship W3211117524A5072363263 @default.
• W3211117524 hasAuthorship W3211117524A5073007668 @default.
• W3211117524 hasBestOaLocation W32111175241 @default.
• W3211117524 hasConcept C121608353 @default.
• W3211117524 hasConcept C126322002 @default.
• W3211117524 hasConcept C167135981 @default.
• W3211117524 hasConcept C2779802037 @default.
• W3211117524 hasConcept C71924100 @default.
• W3211117524 hasConceptScore W3211117524C121608353 @default.
• W3211117524 hasConceptScore W3211117524C126322002 @default.
• W3211117524 hasConceptScore W3211117524C167135981 @default.
• W3211117524 hasConceptScore W3211117524C2779802037 @default.
• W3211117524 hasConceptScore W3211117524C71924100 @default.
• W3211117524 hasIssue "1" @default.
• W3211117524 hasLocation W32111175241 @default.
• W3211117524 hasLocation W32111175242 @default.
• W3211117524 hasOpenAccess W3211117524 @default.
• W3211117524 hasPrimaryLocation W32111175241 @default.
• W3211117524 hasRelatedWork W1985280691 @default.
• W3211117524 hasRelatedWork W2021331582 @default.
• W3211117524 hasRelatedWork W2039636470 @default.
• W3211117524 hasRelatedWork W2324013405 @default.
• W3211117524 hasRelatedWork W2416767700 @default.
• W3211117524 hasRelatedWork W3210359220 @default.
• W3211117524 hasRelatedWork W4232113911 @default.
• W3211117524 hasRelatedWork W4249502477 @default.
• W3211117524 hasRelatedWork W4367672288 @default.
• W3211117524 hasRelatedWork W4285678566 @default.
• W3211117524 hasVolume "116" @default.
• W3211117524 isParatext "false" @default.
• W3211117524 isRetracted "false" @default.
• W3211117524 magId "3211117524" @default.
• W3211117524 workType "article" @default.